Multiple Myeloma Hub cover art

All Episodes

Multiple Myeloma Hub — 94 episodes

#
Title
1

EHA2026 | What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM?

2

Strategies for managing belantamab mafodotin-associated ocular toxicities

3

Integrating BCMA-directed bispecific antibodies into the treatment paradigm for MM

4

EHA2026 | What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM?

5

What’s on the horizon for relapsed/refractory MM in 2026?

6

CELMoDs for the treatment of newly diagnosed and HR smoldering MM

7

CELMoDs for the treatment of relapsed/refractory MM

8

CELMoDs: Mechanism of action and immunomodulatory activity in MM

9

The patient experience: Treatment with BCMA-directed therapies in relapsed MM

10

Optimizing BCMA-directed therapies: Balancing efficacy, safety, and PROs

11

Overview of BCMA-directed therapies for multiple myeloma

12

Quality-of-life considerations with BCMA‑directed therapies for MM

13

Symposium | Practical considerations when sequencing novel agents and managing AEs with BCMA-directed therapies

14

Symposium | Future directions with novel and established BCMA-DT in the MM treatment paradigm

15

Symposium | Real-world insights and clinical experience with BCMA‑directed therapies

16

Symposium | BCMA-directed therapies in MM: Current applications and the evolving clinical landscape

17

What are the latest updates from the phase I trial of P-BCMA-ALLO1 for the treatment of RRMM?

18

Improving access to CAR T-cell therapy for eligible patients with MM

19

ASH 2025 | CARTITUDE-4: Long-term PFS outcomes with cilta-cel for standard-risk RRMM

20

Clinical experience with belantamab mafodotin: Management strategies for ocular toxicity

21

MIDAS: MRD-driven strategy after Isa-KRd induction in ND ASCT-eligible MM

22

How might the clinical development of CELMoDs impact the treatment paradigm for MM?

23

CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT

24

Evolving diagnostic criteria for high-risk smoldering MM

25

What combination regimens including BiTEs are being evaluated for the treatment of RRMM?

26

Risk stratification and prognosis in smoldering MM

27

What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM?

28

How can neurotoxicity associated with CAR T-cell therapy in MM be managed?

29

What might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD?

30

What is the rationale for early intervention in high-risk smoldering MM?

31

How are BCMA-directed bispecific antibodies currently utilized in real-world practice for MM?

32

MRD in MM: Implications for clinical practice and trial design

33

Targeting XPO1 for the treatment of MM: Real-world evidence

34

How to incorporate novel therapies into the treatment paradigm for early RRMM?

35

What are the future perspectives for anti-CD38 mAbs in the treatment of MM?

36

What are the current treatment recommendations and unmet needs in early RRMM?

37

What is the rationale for treating early RRRM with targeted therapies?

38

What is the impact of belantamab mafodotin on QoL in patients with MM?

39

What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma?

40

Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma

41

Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4

42

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma

43

Teclistamab: real-world safety and efficacy

44

Infections associated with bispecific antibodies

45

CAR T-cell therapies in clinical practice

46

How to select maintenance therapies post-ASCT for patients with high-risk MM?

47

Should risk-adapted MM treatment be informed by age or frailty status?

48

How is the immune reconstitution in patients who stop therapy after achieving MRD negativity?

49

What are the main discrepancies between MM treating centers in Brazil?

50

What are the initial data of dara-CyBorD in patients with extramedullary disease?

51

Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?

52

Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM

53

The role of consolidation after autologous stem cell transplantation

54

What are the pros and cons of bispecific antibodies for multiple myeloma?

55

Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM

56

Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?

57

Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM

58

Should 'cure' be the goal for multiple myeloma?

59

Treating elderly and frail patients with MM: Cure versus disease control

60

Is transplantation still relevant? If yes, in what context?

61

The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?

62

Is the treatment of high-risk SMM the way for achieving the cure?

63

Does 'cure' have a different meaning in MM?

64

How to treat first relapse in lenalidomide-refractory MM?

65

With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk MM?

66

When BCMA-directed therapy is not an option, how should we treat late relapse?

67

What do you need to remember when facing CAR T-cell toxicities?

68

What are the key additions to the new NCCN guidelines for multiple myeloma?

69

If maintenance after induction reduces therapy options at relapse, is it still worth it?

70

New findings on the role of the immune microenvironment presented at ASH 2020

71

ASH 2020 discussion: Looking for the best partner for lenalidomide maintenance after auto-SCT

72

Should we still use high-dose melphalan in the era of novel agents?

73

What are the unmet needs in AL amyloidosis in Europe?

74

ASH 2020 discussion: The role of upfront transplant consolidation in the era of novel agents

75

Can single cell sequencing help to better define and monitor MM?

76

My experience with novel immunotherapies

77

How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease

78

Melphalan flufenamide (melflufen) + novel agents for RRMM

79

Isatuximab plus KRd for high-risk NDMM

80

Novel approaches in multiple myeloma: what is unique about CELMoDs?

81

Hot topics in MM: quadruplets and anti-BCMA therapy

82

Genomics of high-risk myeloma

83

The association between the diversity of the oral microbiome and PFS

84

Novel approaches in multiple myeloma: BFCR4350A

85

Updates from the KarMMa trial

86

Update from CARTITUDE-1 | What's new since ASH?

87

Novel approaches in multiple myeloma: TAK-079

88

Should we use KRd or VRd for patients with NDMM?

89

What is the optimal treatment for bone lesions, including patients with renal insufficiency?

90

Recent advances in our understanding of myeloma progression

91

Quadruplet combinations in transplant-ineligible NDMM: isatuximab + Vd + cyclo or len

92

How I treat elderly patients with NDMM

93

Understanding resistance mechanisms to current standard of care and how to overcome them

94

What is plasma cell leukemia and what are the latest advances in treatment?